View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 12, 2017updated 13 Jul 2022 10:08am

NIH reports positive final data from Ebola vaccine trial in Africa

The National Institutes of Health (NIH) in the US has reported positive final results from a clinical trial of two Ebola vaccine candidates, cAd3-EBOZ and rVSV-ZEBOV, performed in Liberia, Africa.

The National Institutes of Health (NIH) in the US has reported positive final results from a clinical trial of two Ebola vaccine candidates, cAd3-EBOZ and rVSV-ZEBOV, performed in Liberia, Africa.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

cAd3-EBOZ was co-developed by the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Centre and GlaxoSmithKline (GSK), while rVSV-ZEBOV was initially engineered by the Public Health Agency of Canada scientists and later licensed to Merck.

The results showed that the vaccines do not have safety concerns and could induce year-long immune responses by one month from initial vaccination.

Sponsored by NIAID, the randomised, placebo-controlled trial is being conducted under the Partnership for Research on Ebola Virus in Liberia (PREVAIL) clinical research collaboration between the US and Liberia.

The PREVAIL 1 trial, which was initiated in February 2015, evaluated 1,500 adults aged 18 and above during an Ebola outbreak in the region.

NIAID director Anthony Fauci said: “This clinical trial has yielded valuable information that is essential for the continued development of these two Ebola vaccine candidates and also demonstrates that well-designed, ethically sound clinical research can be conducted during an epidemic.

“A safe and effective vaccine would be a critically important addition to classical public health measures in controlling inevitable future Ebola outbreaks.”

During the trial, the researchers assessed blood samples of the participants before vaccination and at one week, one month, six months and one year after vaccination.

It was observed that by one month 71% of cAd3-EBOZ and 84% of rVSV-ZEBOV recipients developed an antibody response compared to 3% with placebo.

The responses were found to be maintained at one year with 64% of cAd3-EBOZ and 80% rVSV-ZEBOV recipients having an antibody response compared to 7% placebo recipients.

Furthermore, the trial revealed that the proportion of participants developing malaria by one year was less in case of the vaccine candidate recipients, compared to placebo.

The researchers believe that additional studies are required to determine if the finding has any significance associated with cross-reactive immunity.


Image: A volunteer receives an injection in the PREVAIL Ebola vaccine clinical trial in Liberia. Photo: courtesy of PREVAIL.


 

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena